LMC France's video on International CML Awareness Day!


WORLDWIDE CML AWARENESS DAY - September 22... por lmcfrance

Stopping CML therapies and eradicating CML: Patient perspective from EHA

Recent CML therapies have turned CML into a chronic disease for most patients. However, even if most patients are responding well, some of them suffer from side effects, from being reminded day by day that they have cancer, or struggle to be fully adherent to a life-long medication. In addition, due to the excellent survival rates of CML patients on current therapies, the economical burden of CML rises. From these perspectives, being able to stop therapies at some point in time has become a desirable goal. Two potential pathways towards achieving that goal were discussed at EHA2011: "Operational cure" by stopping TKI therapy in case of stable complete molecular response, and new approaches to eradicate residual cancerous stem cells.

Read more ...

Updated first line data of Nilotinib, Dasatinib and Bosutinib presented at EHA 2011

 

At the European Hematology Association's Annual Congress 2011 in London, CML experts presented updates on the first line trials with Nilotinib, Dasatinib and Bosutinib. The following summarizes the findings from a patient's perspective.

Read more ...

Reporte ASH 2010: ¿La llegada de una nueva era en el tratamiento de primera línea para la LMC?

ash_miniComo todos los años, alrededor de 30.000 médicos, investigadores y representantes de la industria en todo el mundo se reunieron en los Estados Unidos para debatir acerca de las últimas novedades en leucemias y otras enfermedades hematológicas. Aunque “el ASH” está pensado como un evento donde se reúnen exclusivamente profesionales de la salud, alrededor de 30 representantes de pacientes con LMC, mieloma y linfoma, por ejemplo, asistieron para seguirlo, debatir y difundir las noticias.

Read more ...

"CML Advocates Network" now connects 40 leukaemia patient groups

The "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 40 organisations across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives.

Read more ...

Recuerdos de ASH 2009 – por qué volví a ir…

ASH 2009“¿Por qué siempre paso el día de San Nicolás en los Estados Unidos, en vez de con mi familia?”, me pregunté mientras subía al avión hacia los EEUU el 4 de diciembre, para comenzar un viaje de 16 horas a Nueva Orleans, llegar con jet lag, recluirme durante días en los calabozos de un enorme centro de convenciones, sin conocer la ciudad en la que estaba. Año tras año, más de 20.000 hematólogos y cuidadores de la salud asisten a la reunión anual de la Asociación Americana de Hematología, también conocida como ASH. Sus publicaciones están disponibles en Internet. “¿Realmente vale la pena ir, en vez de usar la web?”, pensé. Definitivamente, lo vale.

Read more ...

Now 63 patient organisations from 50 countries are members of the CML Advocates Network

cmlan_150pxThe "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 63 organisations from 50 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest members CML Life from Slovakia, AIL from Italy, CML-STOP from Russia, ASOPALEU from Guatemala and ALMA from Argentina!

Read more ...

Now 69 patient organisations from 55 countries are members of the CML Advocates Network

cmlan_150pxThe "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 69 organisations from 55 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest member Max Smiles from Thailand! See the list of CML groups in the Network, and our worldwide map.

Now 71 patient organisations from 57 countries are members of the CML Advocates Network

cmlan_150pxThe "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 71 organisations from 57 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest members Korea Blood Cancer Association from South Korea, and The Leukemia, Lymphoma, Myeloma Patients Research and Education Society (LLMBIR) from Turkey! See the list of CML groups in the Network, and our worldwide map.

Please donate!

Please donate!

LogIn

EU e-Privacy Directive